About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease

Citation:

European Cardiology Review 2014;9(1):10–5

The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology

Citation:

European Cardiology Review 2014;9(2):65–70

Statins: Practical Considerations – A Review

Citation:

European Cardiology Review 2014;9(2):71–5

Current Treatment of Familial Hypercholesterolaemia

Citation:

European Cardiology Review 2014;9(2):76–81